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The investigation of sudden death is one of the few enduring responsibilities of the Coronial 
system that had its origins in 11
th
 century Britain and was formally established by the articles of 
Eyre in 1194.
1
 Persons finding a body from a sudden or unnatural death were required to raise 
the "hue and cry" and to notify the coroner. 
Although the familial nature of sudden death, including from structural and electrical 
cardiomyopathies, has been recognized for many decades or more, British pathologist MJ 
Davies
2
 in 1999 may be the first to suggest that the family might be approached in the evaluation 
of sudden cardiac death. In the same year, Ackerman and colleagues
3
 used molecular diagnosis 
to identify the cause of sudden cardiac death in a 19-year-old who died after near-drowning, 
heralding the era of what would be called the molecular autopsy. (Of note, the decedent’s mother 
had a definitely prolonged QT interval) Shortly thereafter, clinical genetic testing for inherited 
arrhythmia conditions became increasingly available. 
Potential approaches to identifying heritable causes of sudden cardiac death include 
family assessment, molecular assessment or a combined approach. (See table) 
4-16
 
Behr and colleagues
4
 clinically evaluated 147 first-degree relatives of 32 sudden arrhythmia 
death syndrome (SADS) victims with a 22% diagnostic yield for the cause of SCD, whereas 
more recently, in a larger cohort of victims, a 13.5% yield was identified.
5
 Recent studies of the 
molecular autopsy approach using gene panels of varying sizes
6-8
 or whole exome sequencing
9
 
have identified varying diagnostic yields averaging of 13%. Large studies using a combined 
approach of family assessment combined with molecular diagnosis of decedent and/or family 
members provided larger diagnostic yields than family or molecular assessment alone, with an 
averaged combined diagnostic yield of 31%. 
In the current study,
17
 Lin and colleagues have performed an evaluation of 89 cardiac 
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channelopathy and cardiomyopathy genes in a sudden unexpected death cohort of 296 decedents, 
applying a statistical framework to filter candidate causal variants based on factors that include 
prevalence and penetrance of the diseases related to those variants
18
 and reporting the results 
according to the recent ACMG framework.
19
 Using these stringent guidelines, they identified 17 
pathogenic or likely pathogenic (P/LP) variants in 16 subjects, or 5.4% of their cohort. 
However, the authors also identify 46 novel variants, and 130 variants with allele counts lower 
than that expected on the basis of their related disease. This finding demonstrates the high 
stringency of ACMG guidelines, for which novelty or rarity represent only a single moderate 
criterion for pathogenicity. In the absence of family data (identifying a de novo or segregating 
status for the variant) or a well-established functional assay, such variants will not fulfill P/LP 
status. 
A specific comparison to the recent study of Lahrouchie and colleagues
11
 is warranted, as 
that study also applied ACMG criteria. Lin et al.
17
 used GNOMAD instead of EXAC and this 
may have given rise to different minor allele frequencies that may have altered yield in the 
Lahrouchi paper. There is lack of data on frequent rare variants or disease associated variants in 
non-Caucasian ethnic groups. The Lahrouchi study was predominantly white Caucasian 
compared to 50% African American in the current study. The lack of available family data 
limited the ability to upgrade VUSs to P/LP. This was helpful with supporting pathogenicity for 
a number of novel variants using family segregation or confirmation of de novo variants in the 
Lahrouchie paper. 
In parallel with sudden cardiac death investigation, a system for investigation of 
survivors of sudden cardiac arrest (SCA) and their family members is becoming increasingly 
important. Assessment of SCA survivors (and their family members) may provide an even higher 
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diagnostic yield than SCD victims,
14
 as the proband demonstrating the clearest disease 
penetrance is thus available for both detailed clinical and genetic assessment.  In the assessment 
of such cardiac arrest survivors, clinical assessment again appears to provide a higher diagnostic 
yield
15
 than genetic assessment alone.
16
 
The authors are somewhat unique as a large medical examiner’s office performing their 
own sequencing and variant interpretation, as opposed to most coroner/M.E. systems that use 
commercial labs for this work. While part of the rationale for this is the wide variation of 
reporting from commercial laboratories, representatives from such labs did contribute to ACMG 
guidelines and most are now using the ACMG framework for reporting. It seems infeasible for 
small to moderate Coroner/ME programs to reproduce the described system.  It would be of 
interest to know how the variant identification and interpretation process reported compares to 
that within heritable heart disease clinics in the New York City region, and whether hospital 
based clinics have to repeat or ‘reinterpret’ this process once a patient is sent for consultation. (A 
potential problem if systems are not integrated) 
While coroners and medical examiners should provide an opinion regarding what cardiac 
disease was or might have been present following a detailed examination and death investigation, 
this should be seen as only the beginning of the assessment. The evaluation of the family (in 
which genetic contribution are suspected to have played a role) in subspecialty clinics provides 
another layer of information that is complementary to death investigation, and aligns the 
responsibility of identifying a familial cardiac condition with those who will care for that family 
going forward. 
Beyond sequencing and variant interpretation, coroner and ME offices and pathologists 
aim to improving recognition of appropriate pathological entities by integrating investigations 
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with pathological examinations (getting the phenotype right), keeping the needs of inherited 
arrhythmia clinics in mind and maximizing information transfer, communicating with families 
and encouraging families to attend those clinics. 
It is equally critical that geneticists and cardiologists embrace the efforts of death 
investigation systems to assist with these cases. A fruitful approach for the clinical community 
may involve guiding the efforts of death investigators through education, highlighting examples 
of appropriately integrated systems and actively reaching out to pathologists and coroners to 
improve collaboration and integration of their activities into clinical practice guidelines to 
establish a ‘standard of care’. The cardiac pathology community is a great bridge in this 
endeavour. 
It may be neither appropriate nor rewarding to wait for a molecular autopsy result. After 
an appropriate mourning period, family evaluation as advised by guidelines
 20
 yields important 
clinical diagnoses.
4,10,12
 The overall yield of clinical diagnoses in SADS families is 
approximately 30% when summarizing currently known studies.
21
 Lahoruchi et al
11
 found that in 
82 families diagnoses were made in 29% with clinical evaluation and 22% with molecular 
autopsy. Combined this yielded 39% of families with clinical and/or molecular diagnoses, with 
8-9% sharing clinical and molecular diagnoses. Ideal management therefore requires both 
molecular autopsy and family evaluation to achieve the optimal findings. 
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Table: 
 
Family Assessment Only 
Year Author Jurisdiction Date Range Subjects Number  Clinical Yield  
2003 Behr et al.4 England 2002 
sudden arrhythmic death syndrome 
(SADS) 
32 (147 1° relatives)  22% (7/32)  
2014 Giudici5 
London and 
Milan 
2003-2013 autopsy-negative SUD (1 to 50 yr.) 52 families  13.5% (7/52)  
Genetic Assessment Only 
Year Author Jurisdiction Date Range Subjects Number Genes Genetic Yield  
2017 Dewar et al.8 Manitoba 1998-2013 autopsy-negative child SUD ≤5 yrs. 191 71 6.3%  
2014 Wang et al.6 New York City 2008-2012 autopsy-negative SUD (0 to 58 yr.) 274 (141<1yr.) 6 13.5% to 19.8%  
2014 Bagnall et al.9 Sydney 2005-2009 SUD age 1 to 40 yr. 28 Exome 10% to 31%  
2015 Farrugia et al.7 Strasbourg  autopsy-negative SUD age <35 yr. 16 22 18.8%  
Genetic and Family Assessment 
Year Author Jurisdiction Date Range Subjects Number Genes Genetic Yield Clinical Yield Combined Yield 
2005 Tan et al.18 Amsterdam 1996-2003 sudden unexpected death age < 40 yrs. 43 families 
targeted based 
on phenotype 
23% (10/43) 40% (17/43) 40% (17/43) 
2017 Lahrouchi et al.13 Multiple 
2000-2015 
Overlapping 
Cohorts 
autopsy-negative SUD age 1 to 68 yrs. 302 77 
13% (40/302) 
22% 18/82 
26% (21/82) 39% (32/82) 
2008 Behr et al.19 
St. George’s 
Hospital, London 
 autopsy-negative SUD age 4 to 64 yrs. 57 families 12* 14% (8/57) 51% (29/57) 53% (30/57) 
2013 Hofman et al.13 Amsterdam 1996-2011 sudden unexpected death age < 45 yrs. 372 families 
targeted based 
on phenotype 
18% (67/372) 25% (93/372) 29% (108/372) 
2013 Kumar et al.14 Melbourne 2007-2012 SUD 109 
targeted based 
on phenotype 
  18% (19/109) 
Cardiac Arrest Survivors 
2013 Kumar et al.14 Melbourne 2007-2012 SCA Survivor 52 
targeted based 
on phenotype 
  62% (32/52) 
2016 Herman et al.15 Canada 2004-2013 SCA Survivor age 18 to 88 yrs. 200   34 to 41%  
2017 Mellor et al.16 Canada 2006-2015 SCA Survivor 174 
targeted based 
on phenotype 
17% (29/174)   
 
